These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35585597)

  • 1. Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.
    Zou J; Wang S; Chai N; Yue H; Ye P; Guo P; Li F; Wei B; Ma G; Wei W; Linghu E
    J Nanobiotechnology; 2022 May; 20(1):233. PubMed ID: 35585597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
    Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
    Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
    Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
    Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized drug screening using patient-derived organoid and its clinical relevance in gastric cancer.
    Zhao Y; Li S; Zhu L; Huang M; Xie Y; Song X; Chen Z; Lau HC; Sung JJ; Xu L; Yu J; Li X
    Cell Rep Med; 2024 Jul; 5(7):101627. PubMed ID: 38964315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
    Yoon C; Lu J; Kim BJ; Cho SJ; Kim JH; Moy RH; Ryeom SW; Yoon SS
    J Gastrointest Surg; 2023 Apr; 27(4):666-676. PubMed ID: 36627466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
    Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S
    Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer.
    Chen G; Han R; Wang L; Ma W; Zhang W; Lu Z; Wang L
    Cancer Cell Int; 2024 Aug; 24(1):288. PubMed ID: 39143546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
    Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W
    Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
    Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
    J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel.
    Wu G; Qin XQ; Guo JJ; Li TY; Chen JH
    Int J Clin Exp Pathol; 2014; 7(4):1449-58. PubMed ID: 24817940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
    de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
    Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer.
    Hong C; Wang D; Liang J; Guo Y; Zhu Y; Xia J; Qin J; Zhan H; Wang J
    Theranostics; 2019; 9(15):4437-4449. PubMed ID: 31285771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2016 Dec; 36(12):6699-6703. PubMed ID: 27920005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA PLEC acts as a sponge of microRNA-198 to promote gastric carcinoma cell resistance to paclitaxel and tumorigenesis.
    Zhou N; Wang W; Xu C; Yu W
    Pathol Res Pract; 2021 Aug; 224():153487. PubMed ID: 34225215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
    Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
    J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.